Kontakte:Errol Zhou (Mesye.)
Tel: plis 86-551-65523315
Mobile/WhatsApp: plis 86 17705606359
QQ:196299583
Skype:lucytoday@hotmail.com
Imèl:sales@homesunshinepharma.com
Ajoute:1002, Huanmao Bilding, No.105, Mengcheng Wout, Hefei Vil, 230061, Lachin

CAS NON: 198904-31-3
Molekile Fomil: C38H52N6O7
Molekile pwa: 704,85500
EINECS NON: 812-543-8
MDL NON: MFCD08435966
Pwodwi deskripsyon:
Non pwodwi: Atazanavir CAS non: 198904-31-3
Synonyms:
methylN-[(2S)-1-[2-[(2S, 3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]ino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl) méthyle] hydrazinyl]-3, 3-dimethyl-1-oxobutan-2-yl] carbamate;
Zrivada;
UNII-QZU4H47A3S;
Chimik &PhysicalProperties:
Aparans: Cristalline solid
Asdi: ≥99,0%
Dansite: 1.178 g/cm3
Wouj Point: 207-209 ° c
Refractive endeks: 1,562
Atazanavir, vann anba non komes la Reyataz, se yon Dwog antiretroviral nan inibite protease (PI) klas la. Tankou lot antiretrovirals, li itilize pou trete enfeksyon nan viris immunodeficiency imen (VIH).
Atazanavir se distenge soti nan lot PIs nan ke li ka bay yon fwa-chak jou (olye ke mande doz miltip pou chak jou) e li gen pi piti Efe sou pwofil lipid pasyan an (kantite kolestewol ak lot sibstans wann nan san an). Tankou lot inhibiteurs protease, li itilize selman nan konbinezon ak lot medikaman VIH. Administrasyon pou manje ak medikaman nan Etazini (FDA) apwouve atazanavir jen 20, 2003. Atazanavir se premye PI ki apwouve pou yon fwa-chak jou dosing, epi tou paret yo dwe mwens chans lakoz lipodystrophy ak kolestewol elve kom Efe segonde. Li kapab tou pa dwe kwa-reziste ak lot PIs. Le stimulé ak ritonavir li se ekivalan nan pisans nan lopinavir pou itilize nan terapi sovtaj nan pasyan ki gen yon degre nan rezistans Dwog, byenke ranfose ak ritonavir redui avantaj yo etabolik nan atazanavir.
Li se sou lis Oganizasyon sante mondyal la nan medikaman Esansyel, medikaman ki pi enpotan ki nesese nan yon sistem sante debaz.
Si ou enterese nan pwodwi nou yo oswa gen nenpot kesyon, tanpri santi yo lib yo kontakte nou!
Pwodwi anba patant yo ofri pou R &D objektif selman. Sepandan, responsablite final la manti selman ak achte la.
Baj popilè: atazanavir cas 198904-31-3, manifaktire, founise, faktori, achte, an aksyon